The invention discloses a kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and an application thereof. The kit comprises a blocking reagent, an antigen-antibody reaction system, an avidin-oxide enzyme reaction system and a counterstaining drug. The invention is provided based on the relevance between the expression level of ERCC2 in serous ovarian cancer cells/tissues and sensitivity of cells, tissues or a tumor patient as a host to a primary chemotherapeutic drug. Through ERCC2 detection, purposes such as chemotherapeutic sensitivity/drug resistance evaluation, tumor patient discrimination, and primary chemotherapeutic drug tolerability evaluation can be achieved. The method provided by the invention is simple and accurate. The requirement on a sample is not high. Therefore, the kit and the method can be used in large-scale screening or trace researches. When the kit and the method is used in clinical diagnosis and medication guidance, ex vivo cancer tissues of a patient can be acquired for detection after operation, and the detection is characterized in no wound, no pain, and noninvasiveness. The detection can easily be accepted by patients. With the kit and the application, patient lives can be prolonged, chemotherapy pains of the patients can be alleviated, and life qualities of the patients after operations can be improved.